WES.AX Stock Today: January 22 Infinity Sale Prep, Priceline Fallout
Investors in WES.AX are focused on the Wesfarmers Infinity sale after reports that Chemist Warehouse and private equity are preparing for a process following the collapse of Infinity Pharmacy Group. With 54 Priceline stores in receivership and creditors reportedly owed over A$400 million, attention turns to potential recoveries versus write-down risk at API, Wesfarmers’ health unit. We outline the competitive stakes, what to watch into 18 February 2026 earnings, and the key trading levels shaping sentiment in Australia’s pharmacy retail market.
WES.AX price, metrics, and trend
Wesfarmers traded near A$81.12 in the recent session, down about 1.8% on the day, with a range between A$81.12 and A$83.29. Momentum is mixed: RSI sits at 45, ADX at 14 signals no strong trend, while the MACD histogram is slightly positive at 0.16. Bollinger Bands centre on A$81.12, with upper at A$82.08 and lower at A$80.15, suggesting tight, event-driven action.
The stock changes hands at 32.3 times EPS of A$2.58, above long-run Australian retail averages, reflecting quality and stability. Dividend yield stands near 4.27% with a payout ratio of roughly 78%. EV/EBITDA around 19 and ROE above 32% back strong returns. Balance sheet metrics show debt-to-equity near 1.22 and interest coverage of 13.4 times.
Infinity receivership and asset-sale overhang
Infinity Pharmacy receivership leaves 54 Priceline stores under external control, with creditor claims reportedly exceeding A$400 million, according to Real Commercial reporting on the situation and the paused transaction. This overhang raises uncertainty around lease outcomes, supplier terms, and asset recoveries that could flow through to API. Read more background at Real Commercial.
AFR reports Chemist Warehouse and private equity have begun early preparations for the Wesfarmers Infinity sale, which could include parts tied to Priceline’s network. A competitive process may influence valuations and timelines for any Priceline stores sale. This phase matters for pricing power and market share in pharmacy retail. Coverage here: AFR.
API exposure and earnings risk
API Wesfarmers exposure is in focus as investors weigh potential recoveries against impairment risk from receivership outcomes. Intangibles represent roughly 17.7% of assets, so valuation changes could affect results. The Wesfarmers Infinity sale could help price discovery and reduce uncertainty. Watch for clarity on provisioning, store closures or transfers, and updated scenarios in the 18 February 2026 half-year report.
If Chemist Warehouse bids on assets linked to the Priceline network, pharmacy retail dynamics could shift. National buying power, supplier rebates, and franchise support could move, pressuring margins at rivals. For Wesfarmers, outcomes that stabilise store footprints would be helpful. The Wesfarmers Infinity sale therefore doubles as a market structure event, not just a balance sheet clean-up.
Trade setup into results
Technicals are balanced. Price sits near the 50-day average at A$81.26, below the 200-day at A$84.69. ADX near 14 signals range trading. ATR is 1.16, and Keltner channels bracket A$78.98 to A$83.64. Immediate support sits around A$80.15, with resistance near A$82.08 and A$83.29. A close above the 200-day improves momentum.
Key near-term drivers include the Wesfarmers Infinity sale details, receivership asset outcomes, and any Priceline stores sale progress. Also watch Wesfarmers’ 18 February 2026 earnings, dividend guidance, and commentary on API provisioning. Competitive signals from Chemist Warehouse and franchisees, plus regulatory or lease updates, will steer expectations for API and broader health segment profitability.
Final Thoughts
For Australian investors, the Wesfarmers Infinity sale is now a central driver of near-term risk and opportunity. It may set asset prices, shape competitive lines, and determine whether API needs further provisioning. That is why updates on receivership outcomes and bidder interest matter as much as the 18 February 2026 earnings print. From a trading view, ranges are tight and trend strength is low, so headlines can swing price between support and resistance quickly. We will watch for sale milestones, provisioning detail, and any sign that store networks stabilise. A cleaner outcome would reduce uncertainty and improve confidence in the health segment’s earnings base.
FAQs
What is the Wesfarmers Infinity sale and why does it matter?
The Wesfarmers Infinity sale refers to a potential process involving assets tied to Infinity Pharmacy Group’s collapse, intersecting with Priceline-linked sites. It matters because prices set in this process affect recoveries, potential write-downs at API, and the competitive landscape in pharmacy retail, which can influence WES.AX valuation and earnings expectations.
How does Infinity Pharmacy receivership affect API within Wesfarmers?
Infinity Pharmacy receivership introduces uncertainty around leases, supplier terms, and store transfers. That uncertainty can impact API’s provisions, cash flows, and near-term earnings. Clear sale outcomes, better visibility on creditor recoveries, and franchise stability would lower risk. Investors will look for disclosures at Wesfarmers’ 18 February 2026 results.
Are Priceline stores for sale and who might be interested?
Fifty-four Priceline stores remain under receivership. Selected sites could be sold or reassigned as administrators seek solutions. According to AFR, Chemist Warehouse and private equity are preparing for the Wesfarmers Infinity sale process, so they are logical potential bidders for certain assets tied to the Priceline network, subject to terms and due diligence.
What trading levels and dates should WES.AX investors watch next?
Key levels include support near A$80.15 and resistance around A$82.08 to A$83.29. The 50-day average sits near A$81.26 and the 200-day near A$84.69. With ADX around 14, trend is weak and moves may be headline-driven. The next major date is 18 February 2026 for Wesfarmers’ earnings.
Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.
